Morning immunotherapy timing under fire as data questioned
A Nature Medicine study claiming that administering lung cancer immunotherapy in the morning dramatically reduces progression risk versus afternoon dosing is under fire after scientists flag data inconsistencies, with the journal now launching an investigation.